YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Mantwill, Klaus ^a   Naumann, Ulrike ^b   Seznec, Janina ^b   Girbinger, Vroni ^a   Lage, Hermann ^c   Surowiak, Pawel ^c   Beier, Dagmar ^d   Mittelbronn, Michel ^e   Schlegel, Jürgen ^f   Holm, Per S ^a,g  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g XVir Therapeutics GmbH   (Germany)

Author keywords

Cancer stem cells; Oncolytic virus; Temozolomide; Virotherapy; YB 1

Indexed keywords

ONCOLYTIC ADENOVIRUS; SMALL INTERFERING RNA; TEMOZOLOMIDE; Y BOX BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG SAFETY; DRUG SPECIFICITY; EMBRYO; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION;

ADENOVIRIDAE; ANIMALS; ASTROCYTES; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DISEASE MODELS, ANIMAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIOMA; HUMANS; MICE; NEOPLASTIC STEM CELLS; ONCOLYTIC VIRUSES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS; Y-BOX-BINDING PROTEIN 1;

EID: 84884186952     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-216     Document Type: Article

References (64)

1. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiform: prognosis, extent of resection, and survival. J Neurosurg 2001, 95:190-198. 10.3171/jns.2001.95.2.0190, 11780887.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Eng J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 415:105-111.
4. Ailles LE, Weisman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007, 18:460-466. 10.1016/j.copbio.2007.10.007, 18023337.
5. Das S, Srikanth M, Kessler JA. Cancer stem cells and glioma. Nat Clin Pract 2008, 4:427-435.
6. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
7. Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760. 10.1038/nature05236, 17051156.
8. Blough MD, Westgate MR, Beauchamp D, et al. Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol 2010, 12:756-760. 10.1093/neuonc/noq032, 2940656, 20388697.
9. Beier D, Röhrl S, Pillai DR, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008, 68:5706-5715. 10.1158/0008-5472.CAN-07-6878, 18632623.
10. Bleau A, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/AKT pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235. 10.1016/j.stem.2009.01.007, 3688060, 19265662.
11. Molina JR, Hayashi Y, Stephens C, Georgescu MM. Invasive glioblastoma cells acquire stemness and increased AKT activation. Neoplasia 2010, 12:453-463. 2887086, 20563248.
12. Sunayama J, Matsuda KI, Sato A, et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010, 28:1930-1939. 10.1002/stem.521, 20857497.
13. Wu J, Stratford AL, Astanehe A, et al. YB-1 is a transcription/translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Transl Oncogenomics 2007, 2:49-65. 3634714, 23641145.
14. Lu ZH, Books JT, Ley TJ. YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol 2005, 25:4625-4637. 10.1128/MCB.25.11.4625-4637.2005, 1140647, 15899865.
15. Schittek B, Psenner K, Sauer B, et al. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 2007, 120:2110-2118. 10.1002/ijc.22512, 17266041.
16. Bargou RC, Jürchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nature Med 1997, 3:378-380. 10.1038/nm0497-378, 9095165.
17. Kashihara M, Azuma K, Kawahara A, et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol 2009, 4:1066-1074. 10.1097/JTO.0b013e3181ae2828, 19648825.
18. Oda Y, Ohishi Y, Basaki Y, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer:their correlation with activated Akt. LRP/MVP and P-glycoprotein expression. Cancer Sci 2007, 98:1020-1026. 10.1111/j.1349-7006.2007.00492.x, 17459055.
19. Gessner C, Woischwill C, Schumacher A, et al. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur Respir 2004, 23:14-19.
20. To K, Fotovati A, Reispas KM, et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010, 70:2840-2851. 10.1158/0008-5472.CAN-09-3155, 2848879, 20332234.
21. Elias MC, Tozer KR, Silber JR, et al. Twist is expressed in human gliomas and promotes invasion. Neoplasia 2005, 9:824-837.
22. Shiota M, Izumi H, Onitsuka T, et al. Twist Promotes tumor cell growth through YB-1 expression. Cancer Res 2008, 68:98-105. 10.1158/0008-5472.CAN-07-2981, 18172301.
23. Jürchott K, Kuban RJ, Krech T, et al. Identification of y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signature in colorectal cancer cells. Plos Genetics 2010, 6:1-19.
24. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004, 10:5299-5312. 10.1158/1078-0432.CCR-0349-03, 15328165.
25. Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of delta-24-rgd in brain tumor stem cells: Role of autophagic cell death. J Nat Cancer 2007, 99:1410-1414.
26. Eriksson M, Guse K, Bauerschmitz G, Virkkunen P, et al. Oncolytic adenoviruses kill breast initiating CD44 + CD24-/low cells. Mol Ther 2007, 15:2088-2093. 10.1038/sj.mt.6300300, 17848962.
27. Rognoni E, Widmaier M, Haczek C, et al. Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo. Cancer Gene Ther 2009, 16:753-763. 10.1038/cgt.2009.20, 19363467.
28. Holzmüller R, Mantwill K, Haczek C, et al. YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Int J Cancer 2011, 129:1265-1276. 10.1002/ijc.25783, 21710499.
29. Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007, 25:1196-1208. 10.1200/JCO.2006.07.8626, 17401009.
30. Janz M, Harbeck N, Dettmar P, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002, 97:278-82. 10.1002/ijc.1610, 11774277.
31. Beier D, Hau P, Proescholdt M, Lohmeier A, et al. CD133+ and CD133- glioblastoma derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007, 67:4010-4015. 10.1158/0008-5472.CAN-06-4180, 17483311.
32. Major EO, Miller AE, Mourrain P, Traub RG, de Widt E, Sever J. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A 1985, 82:1257-1261. 10.1073/pnas.82.4.1257, 397234, 2983332.
33. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 1994, 91:8802-8806. 10.1073/pnas.91.19.8802, 44694, 8090727.
34. Nevins JR. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 1981, 1981(26):213-220.
35. Glockzin G, Mantwill K, Jurchott K, et al. Characterization of the Recombinant Adenovirus Vector AdYB-1: Implications for Oncolytic Vector Development. J. Virology 2006, 80:3904-3911. 10.1128/JVI.80.8.3904-3911.2006, 1440461, 16571807.
36. Schilling D, Gehrmann M, Steinem C, et al. Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J 2009, 23:2467-2477. 10.1096/fj.08-125229, 2717766, 19289606.
37. Coles LS, Lambrusco L, Burrows J, et al. Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter. FEBS Lett 2005, 579:5372-5378. 10.1016/j.febslet.2005.08.075, 16198352.
38. Sutherland BW, Kucab J, Wu J, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005, 24:4281-4292. 10.1038/sj.onc.1208590, 15806160.
39. Stratford AL, Fry CJ, Desilets C, et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 2008, 10:R99. 10.1186/bcr2202, 2656895, 19036157.
40. Hermisson M, Klumpp A, Wick W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006, 96:766-776. 10.1111/j.1471-4159.2005.03583.x, 16405512.
41. Holm PS, Bergmann S, Jürchott K, et al. YB-1 relocates to the nucleus in adenovirus infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Bio Chem 2002, 277:10427-10434.
42. Mantwill K, Koehler-Vargas N, Bernshausen A, et al. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res 2006, 66:7195-7202. 10.1158/0008-5472.CAN-05-2339, 16849566.
43. Schäfer A, Teufel J, Ringel F, et al. Aldehyde dehydrogenase 1A1 - a new mediator of resistance to temozolomide in glioblastoma. Neuro Oncol 2012, 12:1452-1464.
44. Abrams SL, Steelman LS, Shelton JG, et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010, 9:1781-1791. 10.4161/cc.9.9.11483, 3781182, 20436278.
45. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46:249-279. 10.1016/j.advenzreg.2006.01.004, 16854453.
46. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related " self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008, 26:3015-3024. 10.1200/JCO.2007.15.7164, 18565887.
47. Pallini R, Ricci-Vitiani L, Banna GL, et al. Cancer stem cell analysis and clinical out come in patients with glioblastoma multiforme. Clin Cancer Res 2008, 14:8205-8212. 10.1158/1078-0432.CCR-08-0644, 19088037.
48. Shen H, Xu W, Luo W, et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signalling transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol 2011, 39:558-569. 10.1016/j.exphem.2011.01.013, 21300134.
49. Davies AH, Dunn SE. YB-1 drives preneoplastic progression: insight into opportunities for cancer prevention. Oncotarget 2011, 2:401-406. 3248184, 21576761.
50. Villalva C, Martin-Lanneree S, Cortes U, et al. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastoma: a potential for targeted therapy?. Int J Cancer 2011, 128:826-838. 10.1002/ijc.25416, 20473906.
51. Sherry MM, Reeves A, WU JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009, 27:2383-2392. 10.1002/stem.185, 19658181.
52. Evdokimova V, Tognon C, Ng T, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009, 15:357-359. 10.1016/j.ccr.2009.04.006, 19411064.
53. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
54. Shiota M, Izumi H, Tanimoto A, et al. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009, 69:3148-3156.
55. Thangue N, Rigby P. An adenovirus E1A-like transcription factor is regulated during the differentiation of murine embryonal carcinoma stem cells. Cell 1987, 49:507-513. 10.1016/0092-8674(87)90453-3, 2952280.
56. Fotovati A, Abu-Ali S, Wang PS, et al. YB-1 bridges neural stem cells and brain tumor initiating cells via its roles in differentiation and cell growth. Cancer Res 2011, 71:5569-5578. 10.1158/0008-5472.CAN-10-2805, 21730024.
57. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003. 10.1056/NEJMoa043331, 15758010.
58. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. Engl J Med 2000, 343:1350-1354.
59. Stupp R, Hegi ME, Mason WP, van den Bent MJ, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466. 10.1016/S1470-2045(09)70025-7, 19269895.
60. Quirin C, Mainka A, Hesse A, Nettelbeck DM. Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells. Int J Cancer 2007, 121:2801-2807. 10.1002/ijc.23052, 17724714.
61. Toulany M, Schlickfluß TA, Eicheler W, et al. Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res 2011, 13:R28. 10.1186/bcr2845, 3219189, 21392397.
62. Shideng B, Qiulian W, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-759. 10.1038/nature05236, 17051156.
63. Wl T, Yip GW, Tan PH, et al. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoresistance in nasopharyngeal cancer. Mod. Pathology 2009, 22:282-290.
64. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Therapy 2001, 3:525-538.